Conference Magazine - GoingPublic.de - Deutsches Eigenkapitalforum

t-cell Europe GmbH
Biotechnology
Profile
Founded in 2011
Number of employees 7
Equity (in EUR million) 0.5
Financing needs (in EUR million) 5.5
Positive result from 2016
Revenues in 2010 (in EUR million) -
Revenues in 2011 (in EUR million) -
Revenues in 2012 (e) (in EUR million) -
Revenues in 2013 (e) (in EUR million) -
Contact
Contact person Dr. Claudia Ulbrich
Phone +49-(0) 3 31-27 97 56-90
E-mail c.ulbrich@t-cell.de
Website www.t-cell.de
Address Zeppelinstr.189
14471 Potsdam
Germany
Business field
Making use of its proprietary platform technologies, it is the
objective of t-cell Europe GmbH, a spin-off of the Berlin-
Brandenburg Center for Regenerative Therapies (BCRT), to
develop and commercialise new T-cell-based regenerative
therapies. Its first indication product will be a Treg-cell therapy
following kidney transplants. t-cell’s business strategy
is to develop its T-cell therapy product(s) until the I/IIa
clinical phases have been completed, before licensing it to
biopharma partner(s). t-cell focuses its further activities on
indications, such as the immunosuppressive treatment
following solid organ transplants, the treatment of Graftversus-host
disease following haematopoietic stem cell
transplants, or the treatment of CMV or EBV infections
following solid organ transplants using T-effector cells.
Strategic market position
Capital Seeking Companies
Each year, more than 30,000 patients in Europe and the US
receive kidneys from living or deceased donors. Unfortunately,
it is often the case that the donor organ is recognised
by the patient’s immune system as being “foreign”
and it is thus regularly rejected. To overcome this physiological
yet contra-productive response, physicians have to
put their patients on lifelong therapy with immunosuppressant
drugs. t-cell’s proprietary technology has been
designed to supersede chronic immunosuppression and its
adverse effects by employing regulatory T-cells (Treg). Tregcells
naturally play a key role by preventing overreactions in
our immune system. t-cell’s astute concept uses therapeutic
Treg-cells as a tool to persuade the patient’s immune
system into accepting the foreign kidney as “its own”. The
cell source can either be peripheral blood from the patients
themselves (autologous therapy) or from a matched donor
(allogenic therapy).
Management
t-cell is managed and supported
by an international and
renowned team of professionals:
Dr. med. Claudia Ulbrich,
CEO; Prof. Dr. med. Petra
Reinke, Chief Clinical Advisor
(Head of the “Immunology” field
at BCRT); and Prof. Dr. med.
Hans-Dieter Volk, Chief Scientific
Advisor (Director of BCRT).
Dr. med. Claudia Ulbrich
Planned investment, shareholders / investors
A total of EUR 5.5 million is to be raised in the current
financing round. This amount is sufficient to cover the entire
projected capital requirement for: a) Autologous therapy
following kidney transplants: Pre-clinical development and
clinical development spanning phases I and II, through to
completion of the “Proof of concept: Successful data from
phase I/II clinical trials” milestone, and b) Allogenic therapy
following kidney transplants: Pre-clinical development.
Deutsches Eigenkapitalforum 2012 Page 163